Geneva, Switzerland, May 4th 2015 – EspeRare today announced that the European Medicines Agency (EMA) has granted an Orphan Drug Designation (ODD) for rimeporide, its lead compound for the treatment of Duchenne muscular dystrophy (DMD). DMD is a rare, life-threatening disease affecting boys early in childhood that causes muscle weakness and muscle loss. It is the most common and serious form of paediatric muscular dystrophies.
Find an actor

Medtec Japan Tokyo 201818.04.2018

The exhibition will take place from 18 to 20 April at the Big Sight Exhibition Centre in Tokyo, Japan. BioAlps will...

Gene Predictis - Tests génétiques pour prévenir les risques liés aux effets adverse

Des tests pour réduire les risques d'effets nocifs liés aux médicaments et à la nutrition. Un article de l'AGEFI
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn